LIGAND PHARMACEUTICALS INCORPORATED Equity Securities, FV-NI, Unrealized Gain (Loss)
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of -$13.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-07
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $35.73M.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was -$49.23M.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $14.78M.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $75.89M.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $90.67M.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$34.60M.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $35.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$13.50M 10-Q · filed 2026-08-07 | $1.28M derived: sum of 3 quarters · filed 2026-08-07 | $77.17M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | -$49.23M 10-Q · filed 2026-05-08 | -$34.45M derived: sum of 2 quarters · filed 2026-05-08 | $41.44M derived: sum of 3 quarters · filed 2026-05-08 | $41.44M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | $14.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $90.67M derived: sum of 2 quarters · filed 2026-02-27 | $90.67M derived: sum of 3 quarters · filed 2026-08-07 | $90.67M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $75.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $75.89M derived: sum of 2 quarters · filed 2026-08-07 | $75.89M 10-Q · filed 2025-11-07 | $75.89M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $0.00 10-Q · filed 2026-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-08-07 | -$8.84M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-05-08 | -$8.84M derived: sum of 3 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$8.84M derived: sum of 2 quarters · filed 2026-02-27 | -$34.60M 10-K · filed 2026-02-27 | -$25.79M 10-K · filed 2025-02-28 | ||
| 2024-09-30 | -$8.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$34.60M 10-Q · filed 2025-11-07 | -$25.79M 10-Q · filed 2024-11-08 | |||
| 2024-06-30 | -$25.76M 10-Q · filed 2025-08-08 | |||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | |||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |